Please select preferred method for the calendar invite

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Welcome to

MEDICALLY

Roche’s International Medical Congress Platform. Medical congresses bring together healthcare professionals to share information about their specialties. MEDICALLY compiles and shares Roche and Genentech's congress materials from medical congresses around the world.

Preview the latest congresses

Browse information about latest congresses and view the congress calendar

Sign up or login to unlock the full suite of MEDICALLY features

Sign up or login to unlock the full suite of MEDICALLY features

November 19 - November 23, 2024 / Vancouver, Canada
AMP 2024

Sign up or login to unlock the full suite of MEDICALLY features

November 19 - November 20, 2024 / Chicago, USA / Virtual (Hybrid)
ASGCT Breakthroughs 2024
No result found

Preview the latest medical materials

Take a look at materials from the latest medical congresses

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
This presentation describes the results of an interim analysis of treatment-naïve patients (baseline to month 6) receiving faricimab▼ in the innovative real-world VOYAGER study. The global VOYAGER study investigates the real-world effectiveness, safety, treatment patterns and anatomical features affecting vision outcomes with faricimab▼ in patients with nAMD and DME on a global level. Treatment-naive eyes achieved visual gains and anatomic improvements during the follow-up period.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
This presentation describes the week 16 (interim) results of the phase 3b/4 SALWEEN study. SALWEEN is investigating the efficacy, safety and durability of faricimab▼ in patients with polypoidal choroidal vasculopathy (PCV) from Asian countries, a subtype of nAMD which is highly prevalent in Asia and a population underrepresented in the phase 3 TENAYA/LUCERNE trials. Interim efficacy and safety results have demonstrated robust improvements in vision and anatomy, and complete closure and inactivation of polypoidal lesions in the majority of patients. Faricimab▼ was well tolerated and consistent with the known safety profile of faricimab▼.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Real-World Effectiveness of Faricimab▼ in Patients with Neovascular Age-Related Macular Degeneration: 12-Month Outcomes from the FARETINA-nAMD and FARWIDE-nAMD Studies
This presentation summarizes key clinical outcomes from the real-world FARETINA and FARWIDE studies in patients with treatment-naïve nAMD, demonstrating that real-world faricimab▼ use is effective in improving visual acuity and decreasing CST with acceptable tolerability in patients with nAMD. Additionally, treatment with faricimab▼ is durable with fewer injections required after 6 months suggesting interval extensions.
No result found

Join an ever-growing community

Sign up using LinkedIn or register via email.

Signing up allows you to access exclusive content and personalize your feeds so you see only what’s relevant to you and your practice.